¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019 Á¦15Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ : 2019-05-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019 Á¦15Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ : 2019-05-26
±³À°ÀÏÀÚ : 2019-05-26
±³À°Àå¼Ò : ¿¬¼¼´ëÇб³ ¹é¾ç´©¸® ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : 2019 Á¦15Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ 
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѸð¹ßÇÐȸ  
´ã´çÀÚ : ÇãâÈÆ
¿¬¶ôó : 031-787-7310  
À̸ÞÀÏ : kda@derma.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 55ºÐ  
¼¼ºÎ¼ö°­·á : 500,000¿ø      
ºñ°í Á¤È¸¿ø, ¿¬±¸È¸¿ø(¿¬È¸ºñÆ÷ÇÔ): »çÀüµî·Ï 4¸¸¿ø, ÇöÀåµî·Ï 5¸¸¿øÀüȸ¿ø, ¿¬±¸È¸¿ø(ȸºñ³³ºÎȸ¿ø): »çÀüµî·Ï 2¸¸¿ø, ÇöÀåµî·Ï 3¸¸¿øºñȸ¿ø(ÇǺΰúÀü¹®ÀÇ, °¡ÀÔºñ Æ÷ÇÔ):»çÀüµî·Ï 7¸¸¿ø, ÇöÀåµî·Ï 8¸¸¿øÇǺΰú(Àü°øÀÇ,±ºÀÇ°ü,°øº¸ÀÇ), ¿¬±¸ÁØȸ¿ø: »çÀüµî·Ï 1¸¸¿ø, ÇöÀåµî·Ï 2¸¸¿øÇǺΰú ¿Ü Ÿ°ú ºñȸ¿ø: 50¸¸¿ø(ÇöÀåµî·Ï¸¸ °¡´É)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 09:00~09:15 Epidemiological Studies of Alopecia Areata Using National Health Insurance Service-National Sample Cohort (NHIS-NSC)  ÃÖÁö¿õ(¾ÆÁÖ´ë) 
±âŸ 05-26 ±×·£µåº¼·ë 09:15~09:30 °³È¸½Ä  () 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 09:30~09:45 Skin equivalent assay: an optimized method for testing for hair growth reconstitution capacity of epidermal and dermal cells.  ¹é½Âȯ(¾Æ»êÀÇ·á¿ø) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 09:45~10:00 Induction of alopecia areata in C3H/HeJ mice using polyinosinic-polycytidylic acid (poly[I:C]) and interferon-gamma.  ÀÌ¿µ(Ãæ³²´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 10:00~10:30 Follicle mitochondria as a target for hair loss treatment  Thomas Dawson(A*Star) 
È޽Ġ05-26 ±×·£µåº¼·ë 10:30~10:45 Coffee Break  () 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 10:45~11:05 The kitchen garden roles of DPC cells in bench to clinic for hair disorders.  °­ÈÆ(Ä«Å縯´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 11:10~11:35 Revisiting the pathophysiology of hair loss disorders for better management - a physician-scientist  Manabu Ohyama(Kyorin University) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 11:35~11:45 Quality of life in Korean alopecic patient: nationalwide studies supported by the Korean Hair Research Society  ÃÖ±¤¼º(ÀÎÇÏ´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 11:45~11:55 Neuroendocrine system in hair growth  Koji Sugawara(Osaka City University) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 11:55~12:05 Dermoscopy uses for hair & scalp diseases.  ±è¹®¹ü(ºÎ»ê´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 12:05~12:15 Folliculitis decalvans: Study of clinical and histopathological features  Masaki Uchiyama(Tokyo Medical University) 
½Ä»ç 05-26 ±×·£µåº¼·ë 12:15~13:20 Á¡½É½Ä»ç  () 
Åä·Ð 05-26 ±×·£µåº¼·ë 13:20~14:05 ÀÚÀ¯¿¬Á¦  () 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 14:05~14:35 Efficacy and safety of finasteride for ten years of over 300 AGA patients in Japan.  Akio Sato(Tokyo Memorial Clinic) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 14:35~14:50 The treatment of AGA with 5AR inhibitor in elderly and female patients  À¯¹Ú¸°(°æÈñ´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 14:50~15:05 Tranomic analysis of balding and non-balding scalp in male pattern baldness and female pattern hair loss.  ¹Úº´Ã¶(´Ü±¹´ë) 
È޽Ġ05-26 ±×·£µåº¼·ë 15:05~15:20 Coffee Break  () 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 15:20~15:50 Review Update on Alopecia Areata  Kevin McElwee(Bradford University) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 15:50~16:05 Mechanism: JAK inhibitor and mesenchymal stem cell therapy to treat alopecia areata  ±èÁ¤Àº(Ä«Å縯´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 16:05~16:20 Oral tofacitinib for moderate-to-severe alopecia areata from clinician's view point  ¹ÚÇö¼±(¼­¿ï´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 16:20~16:35 Role of Hair Prostheses (Wigs) in Patients with Severe Alopecia Areata.  ¹ÚÁø(ÀüºÏ´ë) 
±³À°½Ã°£ 05-26 ±×·£µåº¼·ë 16:35~16:50 Therapeutic efficacy and safety of a 1927-nm fractionated thulium laser on pattern hair loss: an evaluator-blinded, split-scalp study.  Á¶¼ººó(¿¬¼¼¼¼¶õÇǺΰú) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019 Á¦15Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ : 2019-05-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ÇѸ²´ëÇб³°­µ¿¼º½Éº´¿ø 2019³â 5¿ù ºñ´¢ÀÇÇаú ¿¬¼ö°­Á : 2019-05-28
´ÙÀ½±Û 2019³âµµ ´ëÇÑÅëÁõÇÐȸ Ãá°è ¿¬¼ö±³À° : 2019-05-26
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20612 ¼­¿ï 2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦12Â÷ Clinical Densitometry Course : 2024-06-23 0 187 2024-04-29
20611 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(2ÀÏÂ÷) : 2024-06-22 0 203 2024-04-29
20610 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 21ÀÏ ±Ý¿äÁý´ãȸ(ÀÌ°ü ÁúȯÀÇ Áø´Ü°ú Ä¡·á) : 2024-06-21 0 185 2024-04-29
20609 °æ±â ¾È»ê ¹× ½ÃÈ­Áö¿ª À̺ñÀÎÈÄ°ú Àǻ縦 À§ÇÑ Áý´ãȸ(¾È¸é¸¶ºñ) : 2024-06-21 0 181 2024-04-29
20608 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(1ÀÏÂ÷) : 2024-06-21 0 158 2024-04-29
20607 ¼­¿ï 2024 ´ëÇÑȯ°æõ½ÄÆóÁúȯÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-21 0 165 2024-04-29
20606 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-¿Ü·¡¿¡¼­ °£´ÜÇÏ°Ô ÇÒ ¼ö ÀÖ´Â À½¼ºÄ¡·á : 2024-06-20 0 222 2024-04-29
20605 ´ë±¸ ´ëÇÑ»êºÎÀΰúÇÐȸ ´ë±¸Áöȸ ¿¬¼ö°­Á : 2024-06-20 0 129 2024-04-29
20604 °­¿ø Á¦171ȸ ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø ¼ÒÈ­±â ¿¬¼ö±³À° : 2024-06-19 0 172 2024-04-29
20603 °æ±â Á¦16ȸ ±¹¸³¾Ï¼¾ÅÍ ±¹Á¦½ÉÆ÷Áö¾ö : 2024-06-19 0 137 2024-04-29
20602 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 4ÀÏÂ÷ : 2024-06-16 0 115 2024-04-29
20601 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-06-16 0 137 2024-04-29
20600 ¼­¿ï 2024 Á¦ 2ȸ ¿¬¼¼´ëÇб³ ¼öºÎ ¹× »óÁö ½ÉÆ÷Áö¾ö : 2024-06-16 0 189 2024-04-29
20599 ¼­¿ï ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ ¿¬¼ö°­Á : 2024 »êºÎÀΰú¹Ì¼º³â¿¬¼ö°­Á : 2024-06-16 0 224 2024-04-29
20598 ±¤ÁÖ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ È£³² ¹× Á¦ÁÖ ¿¬¼ö°­Á : 2024-06-16 0 113 2024-04-29
41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷